Myanmar: Ideal market for digital payments, and now Ant Financial is buying in
- Ant Financial plans to invest US$73.5 million in Myanmar’s digital payments platform, Wave Money
- Myanmar presents an ideal environment for digital payments with low financials and high levels of cash utilisation
- Ant Financial could help Wave Money increase use cases, improve digital infrastructure and user experience
Ant Financial (the operator of Alipay, and an affiliate company of Alibaba) plans to invest US$73.5 million in Myanmar’s digital payments platform, Wave Money. The investment will buy Ant Financial a substantial minority stake, alongside existing shareholders Yoma Group and Telenor. We think Ant Financial, with its global expertise, could help Wave Money more fully capture the opportunities for digital payments in Myanmar by increasing use cases such as international remittances, lending and insurance along with improvement in digital infrastructure and user experience. Relative to neighbouring economies, Myanmar has much lower bank account penetration and higher levels of cash utilisation; it could therefore be a fertile hunting ground for digital payments operators.
Myanmar presents an ideal environment for digital payments:
- Traditional banking penetration is particularly low. Only 26% of adults have an account at a financial institution, versus a median of 49% for neighbouring markets),
- Cash penetration is high. Currency in circulation is at 21% of M2 versus 10% for the peer group.
- Mobile penetration is strong. Mobile subscription rates are more than 100% of the total population.
Digital payments adoption rates in Myanmar have been growing strongly in recent few years. A survey by Kantar TNS, a UK-based market research firm, shows that for people who send and receive money domestically, less than 1% used mobile money in 2016, while this number had exploded to 80% in 2019.
|Account at financial institution (% of adults)||ATMs (per 100k adults)||Mobile subscription (% of total population)||Currency in circulation/M2 ratio|
Source: World Bank, central banks. Note: Mobile and ATM penetration data is for 2018, account penetration is 2017 while currency in circulation data is latest available.
Telecoms, banks and independent operators are all active in digital payments
Currently the Central Bank of Myanmar has licenced only five non-banks to provide mobile financial services (compared to 33 licences issued by State Bank of Vietnam). The five are: Wave Money, M-Pitesan, OK$, My Money, MPT Money.
In addition to these five non-banks, commercial banks are also active in this space, with various banks having their own digital wallet. For example, KBZ Pay is operated by KBZ Bank, CB Pay by CB Bank, OnePay is a group company of AGD Bank, and Ongo has a partnership with MOB Bank.
Myanmar digital payments landscape
Source: Tellimer Research
Wave Money is the leading digital wallet in Myanmar. A joint venture between Telenor and Yoma Group, Wave Money was the first operator to receive a mobile financial services licence from the Central Bank of Myanmar, in 2016. It has subsequently grown strongly and is currently the leading operator in Myanmar with more than 21mn users (49% of the adult population), and over 55,000 agents covering 89% of Myanmar’s territory. The platform had already moved into positive EBITDA territory in 2018. In 2019, it transacted US$4.3bn through its platform (up by more than 200% yoy), which is equivalent to c6% of Myanmar’s GDP, but there is still significant room for growth. For example, Kenya (where M-Pesa has an estimated 85% market share in digital transactions) handled transactions of US$43bn in 2019 (equivalent to 43% of Kenya’s GDP).
With Ant Financial’s expertise, Wave Money could expand its product offerings and strengthen its market position. Ant Financial is the highest-valued fintech in the world (US$150bn as of the 2018 funding round) and its payments arm Alipay is the world’s most popular digital wallet platform, with around 1.2bn users. With such a wide portfolio of relevant businesses, we think Ant Financial could help Wave Money better capture the full potential of Myanmar’s digital payments industry, by sharpening its focus on merchant payments and lifting the number of use cases by introducing new products such as international remittances, lending and insurance. In addition, Ant Financial could help to improve Wave Money’s digital infrastructure and its user experience.
Ant Financial has an extensive presence in Asia. It has invested in various digital payments platforms in Asia including bKash in Bangladesh (investment of cUS$160mn), Easypaisa in Pakistan (a Telenor group company, investment of US$185mn), Vietnam’s eMonkey, India’s PayTM, Ascend Money in Thailand, Mynt in Philippines and Emtek in Indonesia, among others.
Yoma Strategic Holdings can also help develop Wave Money’s business, as a 30% shareholder. It is listed on the main board of the Singapore Securities Exchange Trading Limited and is a leading corporation in Myanmar with a diversified portfolio of businesses in Real Estate, Consumer, Automotive & Heavy Equipment, Financial Services and Investments.
Most Viewed See all latest
- 1 Strategy Note/Global Active investing in EM equity after Covid-19: A final chance against passive
- 2 Weekend Reading/Global Covid-19 business transformations: The subscription revolution
- 3 Equity Analysis/Nigeria Nigeria E-Commerce: The route to profit for ride-hailing and food delivery
- 4 Macro Analysis/Global IMF emergency financing tracker: Where are Angola, Belize, Suriname and Zambia?
- 5 Strategy Note/Global China devaluation another US-China friction and a risk for rival exporters
This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not cons...
Pakistan's Ferozsons enters negotiations for Remdesivir production
- FEROZ is in negotiations with Gilead Sciences to manufacture a Covid-19 treatment drug named Remdesivir
- This is a non-exclusive license agreement where SEARL and Getz Pharma may also be potential candidates
- If FEROZ successfully avails the license agreement, it is likely to fetch the top-end of premium valuations
In an exchange filing yesterday, Ferozsons Laboratories Limited (FEROZ) notified that it has entered negotiations, via its 80% owned subsidiary BF Biosciences Limited (BFBL), to potentially reach a non-exclusive license agreement with US-based Gilead Sciences for the manufacture and sale of Remdesivir in Pakistan and 126 other countries. Remdesivir is a US FDA approved wide-spectrum antiviral drug used to treat advanced stage Covid-19 patients.
However, the non-exclusivity of the agreement opens the field for several other local players and unlike FEROZ’s previous blockbuster drug Sovaldi – an innovator drug, for which it maintained a monopoly until patent expiry. Data from a trial by the National Institutes of Health (NIH) in the United States showed Remdesivir reduced hospitalisation stays by 31% compared to a placebo treatment, but it did not significantly improve survival.
We think Searle Company (SEARL) and Getz Pharma may also be candidates to obtain this license because of their existing presence in biosciences (Hep-C, HIV). Sanofi Pakistan (SAPL) may also potentially emerge with Regeneron Pharmaceuticals with other drugs later in the year, in our view.
Lead time to production is likely to be shorter than Sovaldi
Gilead’s patent on Remdesivir means it has the exclusive rights to produce it. But, under international trade rules, nations defined by the UN as least-developed countries (including Pakistan and Bangladesh) can ignore such patents and make drugs more affordable in their markets.
Remdesivir is one of several repurposed drugs drawing cautious optimism for efficacy in Covid-19 treatment. These drugs are normally indicated for other diseases, where a shortened development timeline and reduced costs for existing compounds is particularly advantageous in a pandemic situation. The lead time to production is expected to be extremely short where Bangladesh’s largest drug makers, Beximco Pharmaceuticals, announced that it will start production in mid-May 2020 (under a similar agreement with Gilead). However, the exact timeline for FEROZ is yet to be determined as (i) negotiations with Gilead are still underway, (ii) sourcing of API remains and (iii) regulatory approval from DRAP have yet to be obtained. We expect it should be shorter than Sovaldi (7 months) due to the urgency of the situation.